Jasper Therapeutics, Inc. (JSPR)

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE

What they're doing

Between 2026-08-02 and 2026-10-31, public records show 2 signals for Jasper Therapeutics, Inc.. Most notable: 2026-09-28: Filed 8-K disclosing director or officer change; 2026-08-26: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.

Generated 2026-10-31 from public records.

Signals, last 12 months

  1. Material 8-K filing
    Filed 8-K disclosing director or officer change
  2. Material 8-K filing
    Filed 8-K disclosing material agreement
  3. Material 8-K filing
    Filed 8-K disclosing material agreement, acquisition or disposition of assets, director or officer change
  4. Material 8-K filing
    Filed 8-K disclosing director or officer change
  5. Material 8-K filing
    Filed 8-K disclosing director or officer change

Insider transactions

DateInsiderRoleCodeSharesPriceValue
2025-09-22WIGGANS THOMAS GdirectorP41,0002.43$99,630
2025-09-22Lucas SvetlanadirectorP20,0002.43$48,600
2025-09-22MARTELL RONdirectorP41,0002.43$99,630
2025-09-22Shizuru Judith AnnedirectorP41,0002.43$99,630
2024-12-12Mahal Jeetinder SinghofficerS90022.11$19,899
2024-12-12Mahal Jeetinder SinghofficerM9007.1$6,390
2024-09-12Mahal Jeetinder SinghofficerM9007.1$6,390
2024-09-12Mahal Jeetinder SinghofficerS90021.23$19,107

Federal contracts

No federal contract actions on record for this recipient mapping.

Lobbying

No federal lobbying filings on record for this client mapping.

Public attention

No Wikipedia pageview data linked to this company.

Recent filings